Intravenous golimumab in rheumatoid arthritis

被引：9

作者：

Cohen, Marc D. ^{[1
]}

Keystone, Edward C. ^{[2
,3
]}

机构：

[1] Mayo Clin, Denver, CO 80218 USA

[2] Univ Toronto, Toronto, ON, Canada

[3] Mt Sinai Hosp, Toronto, ON M5T 3L9, Canada

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2014年 / 10卷 / 07期

关键词：

anti-TNF-; antibodies; golimumab; rheumatoid arthritis treatment; safety of TNF- inhibition; TNF-; inhibition; ALPHA MONOCLONAL-ANTIBODY; NECROSIS-FACTOR-ALPHA; DOUBLE-BLIND; PHASE-III; ANKYLOSING-SPONDYLITIS; METHOTREXATE THERAPY; SAFETY; EFFICACY; PHARMACOKINETICS;

D O I：

10.1586/1744666X.2014.918847

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Intravenous golimumab in a dosage of 2 mg/kg, initially given every 4 weeks but then every 8 weeks, in addition to methotrexate, is effective in the treatment of patients with rheumatoid arthritis. This weight-based infusion is administered over thirty minutes with an acceptable safety profile. Since it is a relatively new formulation, more time will be required to assess its specific role in the rheumatologists' armamentarium and to appreciate more fully its long-term safety.

引用

页码：823 / 830

页数：8

共 50 条

[1] Prescribing Patterns of Intravenous Golimumab for Rheumatoid Arthritis
Brady, Brenna L.
Tkacz, Joseph P.
Lofland, Jennifer
Meyer, Roxanne
Bolge, Susan C.
CLINICAL THERAPEUTICS, 2015, 37 (09) : 2028 - 2036
[2] Golimumab for Rheumatoid Arthritis
Pelechas, Eleftherios
Voulgari, Paraskevi V.
Drosos, Alexandros A.
JOURNAL OF CLINICAL MEDICINE, 2019, 8 (03):
[3] Golimumab for rheumatoid arthritis
Singh, Jasvinder A.
Noorbaloochi, Shahrzad
Singh, Gurkirpal
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (01):
[4] The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
Vance J. Bray
Aaron Broadwell
Herbert S. B. Baraf
Shawn Black
Brenna L. Brady
Joseph Tkacz
Lorraine Yarngo
Raphael J. DeHoratius
Drugs in R&D, 2018, 18 : 211 - 219
[5] The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
Bray, Vance J.
Broadwell, Aaron
Baraf, Herbert S. B.
Black, Shawn
Brady, Brenna L.
Tkacz, Joseph
Yarngo, Lorraine
DeHoratius, Raphael J.
DRUGS IN R&D, 2018, 18 (03) : 211 - 219
[6] LONG TERM SAFETY OF INTRAVENOUS GOLIMUMAB AND COMPARISON WITH SUBCUTANEOUS GOLIMUMAB IN RHEUMATOID ARTHRITIS: RESULTS THROUGH 2 YEARS
Westhovens, R.
Keystone, E.
Bingham, C. O.
Hsia, E. C.
Kim, L.
Zhou, Y.
Mendelsohn, A.
Weinblatt, M.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 469 - 469
[7] Long Term Safety of Intravenous Golimumab and Comparison with Subcutaneous Golimumab in Rheumatoid Arthritis: Results through 2 Years
Westhovens, Rene
Keystone, Edward C.
Bingham, Clifton O., III
Hsia, Elizabeth C.
Kim, Lilianne
Zhou, Yiying
Mendelsohn, Alan M.
Weinblatt, Michael E.
ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S206 - S206
[8] Maintenance of Efficacy and Safety with Subcutaneous Golimumab Among Patients with Active Rheumatoid Arthritis Who Previously Received Intravenous Golimumab
Taylor, Peter C.
Ritchlin, Christopher
Mendelsohn, Alan
Baker, Daniel
Kim, Lilianne
Xu, Zhenhua
Mack, Michael
Kremer, Joel
JOURNAL OF RHEUMATOLOGY, 2011, 38 (12) : 2572 - 2580
[9] Golimumab Therapy of Rheumatoid Arthritis: An Overview
Zidi, I.
Bouaziz, A.
Mnif, W.
Bartegi, A.
Al-Hizab, F. A.
Amor, N. B.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2010, 72 (02) : 75 - 85
[10] Golimumab for Rheumatoid Arthritis: A Systematic Review
Singh, Jasvinder A.
Noorbaloochi, Shahrzad
Singh, Gurkirpal
JOURNAL OF RHEUMATOLOGY, 2010, 37 (06) : 1096 - 1104

← 1 2 3 4 5 →